BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 18572040)

  • 1. Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.
    Ezekowitz JA; Lee DS; Tu JV; Newman AM; McAlister FA
    Am J Cardiol; 2008 Jul; 102(1):79-83. PubMed ID: 18572040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS; Bredikis A; Habib G; Carabello BA; Ramasubbu K; Bozkurt B
    Am J Cardiol; 2008 Nov; 102(10):1356-60. PubMed ID: 18993155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction.
    Tehrani F; Phan A; Chien CV; Morrissey RP; Rafique AM; Schwarz ER
    Am J Cardiol; 2009 Mar; 103(6):829-33. PubMed ID: 19268740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
    Lam PH; Packer M; Gill GS; Wu WC; Levy WC; Zile MR; Brar V; Arundel C; Cheng Y; Singh SN; Allman RM; Fonarow GC; Ahmed A
    Am J Med; 2020 Oct; 133(10):1187-1194. PubMed ID: 32272101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
    Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
    Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
    J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
    Yamaguchi T; Kitai T; Miyamoto T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Yamaguchi J; Iwai T; Hijikata S; Masuda R; Miyazaki R; Hara N; Nagata Y; Nozato T; Matsue Y
    Am J Cardiol; 2018 Apr; 121(8):969-974. PubMed ID: 29477488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
    Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.
    Ahmed A; Rich MW; Love TE; Lloyd-Jones DM; Aban IB; Colucci WS; Adams KF; Gheorghiade M
    Eur Heart J; 2006 Jan; 27(2):178-86. PubMed ID: 16339157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.
    Malik A; Masson R; Singh S; Wu WC; Packer M; Pitt B; Waagstein F; Morgan CJ; Allman RM; Fonarow GC; Ahmed A
    J Am Coll Cardiol; 2019 Aug; 74(5):617-627. PubMed ID: 31370952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
    Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
    Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
    Shah R; Wang Y; Foody JM
    Am J Cardiol; 2008 Jan; 101(2):217-22. PubMed ID: 18178410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors.
    Philbin EF; Rocco TA; Lindenmuth NW; Ulrich K; Jenkins PL
    Am J Med; 2000 Dec; 109(8):605-13. PubMed ID: 11099679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M;
    Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.